IDiyas

For the Inventor, By the Inventor

Poway, CA, United States of America

Brett E Crawford

USPTO Granted Patents = 15 

 

 

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 110(Granted Patents)


Company Filing History:

goldMedal13 out of 135 
 
Biomarin Pharmaceutical Inc.
 patents
silverMedal2 out of 2 
 
Zacharon Pharmaceuticals, Inc.
 patents

Years Active: 2012-2020

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2020-10-06),
2. 10683530 - Detection of oligosaccharides (2020-06-16),
3. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2020-06-09),
4. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2019-04-16),
5. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA (2018-03-13),
6. 9796999 - Detection of oligosaccharides (2017-10-24),
7. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2017-06-13),
8. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2016-05-17),
9. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2015-12-29),
10. 9029530 - Detection of oligosaccharides (2015-05-12),
11. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2014-08-19),
12. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder (2014-07-08),
13. 8592140 - Detection of oligosaccharides (2013-11-26),
14. 8232073 - Quantification of non-reducing end glycan residual compounds (2012-07-31),
15. 8183003 - Polymer end group detection (2012-05-22),

Title: The Inventive Journey of Brett E Crawford

Introduction:

Brett E Crawford, a prolific inventor hailing from Poway, CA, has made significant contributions to the field of biomedical research with a total of 15 patents to his name. His innovative work focuses on the quantification of non-reducing end glycan residual compounds and the detection of oligosaccharides for the diagnosis and monitoring of various diseases.

Latest Patents:

Among his latest patents is the groundbreaking method for quantifying non-reducing end glycan residual compounds to determine the presence, identity, or severity of a disease. Additionally, his invention includes a process for detecting oligosaccharides in biological samples, especially in individuals suffering from disorders associated with abnormal glycosaminoglycan accumulation.

Career Highlights:

Brett E Crawford has been associated with prestigious companies such as Biomarin Pharmaceutical Inc. and Zacharon Pharmaceuticals, Inc., where he has played a key role in driving innovation and advancing healthcare solutions through his patented inventions.

Collaborations:

Throughout his career, Brett E Crawford has collaborated with esteemed colleagues such as Charles A Glass and Jillian R Brown. Together, they have worked towards developing cutting-edge technologies aimed at improving diagnostic and therapeutic approaches in the field of biomedicine.

Conclusion:

In conclusion, Brett E Crawford's innovative spirit and relentless dedication to healthcare innovation have led to groundbreaking advancements in the field of biomedicine. His patents and collaborations stand as a testament to his commitment to improving the lives of individuals affected by various diseases and disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…